Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolism
AssigneeLipigon Pharmaceuticals AB
InventorsFrank JASCHINSKI, Anne SADEWASSER, Sven MICHEL
Life of this patent
Estimating the term…
Abstract
An ANGPTL4 inhibitor consisting of an oligonucleotide has 12 to 22 nucleotides. At least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of human and/or mouse ANGPTL4 and inhibits the expression of ANGPTL4. Also disclosed herein is a pharmaceutical composition of the ANGPTL4 inhibitor and a pharmaceutically acceptable carrier, excipient, diluent, or a combination thereof.
Claims19
An ANGPTL4 inhibitor consisting of an oligonucleotide comprising 12 to 22 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of ANGPTL4 of SEQ ID NO.1 (human), ANGPTL4 of SEQ ID NO. 2 (human), ANGPTL4 of SEQ ID NO.58 (mouse) and/or ANGPTL4 of SEQ ID NO.59 (mouse), wherein the oligonucleotide inhibits the expression of ANGPTL4.
Dependencies are inferred from the claim text.